explained how bispecific antibodies work, and what patients with cancer can expect directly after treatment and longer term. A lot of people are starting to be a little bit more familiar with ...

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma.

Bristol Myers Squibb (NYSE:BMY) is paying up to $11.1B in a licensing agreement to help develop BioNTech's (NASDAQ:BNTX) ...

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s bispecific antibody targeting PD-L1 and VEGF-A, BNT-327, in a deal possibly worth over $11 billion. The companies will ...

Bispecific antibodies first reached patients as cancer treatments, but a growing number of companies are working to expand these therapies to autoimmune diseases. Sanofi is adding a new contender ...

Building on this foundation, bispecific and trispecific antibodies have emerged as innovative biologics aimed at simultaneously engaging multiple targets, promising improved efficacy and safety ...

Biogen Inc. and Biogen MA Inc. (“Biogen”) filed a Complaint for Declaratory Judgment and Permanent Injunctive Relief ...

1xVEGF bispecific antibodies by its VEGF trap, which binds multiple VEGF receptor ligands beyond VEGF-A, a bispecific structure which leverages PD-L1 as an anchor in the tumor microenvironment ...